Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Non Regulatory August 15, 2022Vivesto notes the launch of Apealea® in Germany by Inceptua
-
Regulatory July 21, 2022Vivesto appoints Christer Nordstedt as acting CEO
-
Regulatory July 5, 2022Vivesto winds down its activities in Russia
Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program